Baylor College of Medicine

Nexstim NBS 5+ System Continues to Generate Interest in the US

Retrieved on: 
Thursday, October 6, 2022

Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system.

Key Points: 
  • Lauren Marangell and Rayan Al Jurdi, experts in the treatment of major depression, have purchased a NBS 5+ system.
  • The NBS 5+ system, released in the United States in 2021, combines the capabilities of Nexstims NBS and NBT systems.
  • The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
  • Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

Colossal Accelerates Research and Development of Life-Saving Vaccine to Prevent Elephant Extinction

Retrieved on: 
Wednesday, October 5, 2022

Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, accelerates efforts to end elephant extinction on Earth.

Key Points: 
  • Colossal Biosciences, a breakthrough genetic engineering and de-extinction company, accelerates efforts to end elephant extinction on Earth.
  • Colossal will lead the development of novel treatments and a vaccine to prevent the deadly disease and protect as many elephants as possible - both in zoos and in their natural habitats.
  • Colossal and Dr. Lings lab will accelerate milestones in three phases, including the development and rollout of a protein subunit vaccine, the development of an mRNA vaccine, and the development of a monoclonal antibody treatment.
  • Were thrilled to advance science to benefit both existing and future generations of elephants and mammoths, said Justin Quinn, Colossal Director of Product Development.

2022 "Healthiest 100 Workplaces in America"

Retrieved on: 
Wednesday, October 5, 2022

"This award speaks volumes to employers' investments in employee health beyond traditional physical wellness benefits."

Key Points: 
  • "This award speaks volumes to employers' investments in employee health beyond traditional physical wellness benefits."
  • To qualify for the national award, applicants are also scored on a section called "The Healthiest 100 Workplaces in America."
  • The 2022 Healthiest 100 Workplaces in America, with their headquarters location and number of employees, are:
    Baylor College of Medicine (Houston, Texas 10,962)
    National Association of Insurance Commissioners(Kansas City, Mo.
  • 1,661)
    Jamestown Board of Public Utilities (Jamestown, N.Y. 150)
    Highmark Blue Cross Blue Shield of Western New York(Buffalo, N.Y. 1,400)
    Johnson Kendall & Johnson (Newtown, Penn.

TEXAS-DEVELOPED PATENT-FREE COVID-19 VACCINE TECHNOLOGY RECEIVES EMERGENCY USE AUTHORIZATION IN INDONESIA

Retrieved on: 
Friday, September 30, 2022

Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.

Key Points: 
  • Itreceived emergency use authorization in Indonesia, as a primary vaccine in adults.
  • Indonesia is seeking Halal Certification for the vaccine since no animal cells or products were used in the production of the vaccine.
  • The pharmaceutical company is currently manufacturing Covid-19 primary series vaccine, while booster vaccine is in the clinical trial stage and soon followed by vaccine for children.
  • Bio Farma became a holding company after a merger of three listed state-owned pharmaceutical companies in Indonesia.

Final Call To Apply For The 2022 Biocodex Microbiota Foundation $50,000 U.S. Research Grant

Retrieved on: 
Monday, September 26, 2022

BEDMINSTER, N.J.,  September 26, 2022 /PRNewswire-PRWeb/ -- With the submission deadline approaching, the Biocodex Microbiota Foundation is calling for final grant applications from early-career investigators studying gut microbiota in human health and disease, including Covid-19, sleep disorders, the brain-gut axis and other evolving gut health research. The $50,000 research grant, now in its 6th year, is juried by a panel of medical and scientific experts in the field and can be applied to a new or existing study. The application can be downloaded here and deadline for entry is October 1, 2022, 5PM EST.

Key Points: 
  • This is the sixth consecutive year the Biocodex Microbiota Foundation has awarded the $50,000 US grant, which aims to advance research and understanding of human microbiota.
  • Other Biocodex Microbiota Foundation $50,000 grant recipients include:
    The Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to recognize the interaction between microbiota and different pathologies.
  • To learn more information about Biocodex Microbiota Foundation and the 2022 US grant program, click here .
  • About the Biocodex Microbiota Foundation:
    The Biocodex Microbiota Foundation's mission is to support research into microbiota and its interaction with various pathologies.

Duncan NRI at Texas Children's Hospital Accelerates Neurological Research and Therapies with Historic $10M Gift from The Blue Bird Circle

Retrieved on: 
Friday, September 23, 2022

HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.

Key Points: 
  • HOUSTON, Sept. 23, 2022 /PRNewswire/ -- The Jan and Dan Duncan Neurological Research Institute (Duncan NRI) at Texas Children's Hospital today announced it received a $10 million donation from The Blue Bird Circle.
  • This historic donation is being made to commemorate the Blue Bird Circle's upcoming centennial anniversary and brings the organization's gifts to Texas Children's to over $25 million which will help advance life-changing neurological research at the Duncan NRI.
  • At Texas Children's Hospital Blue Bird Clinic, Blue Bird volunteers log more than 5,000 hours a year in administrative assistance the equivalent of three full-time employees.
  • The volunteers' time, effort, and donations help support The Blue Bird Circle Clinic for Pediatric Neurology at Texas Children's Hospital.

Ellison Institute Welcomes Dr. Reva Basho as new Director of the Women's Cancer Program

Retrieved on: 
Wednesday, September 21, 2022

LOS ANGELES, Sept. 21, 2022 /PRNewswire/ -- The Lawrence J. Ellison Institute for Transformative Medicine announced today the appointment of Dr. Reva Basho as the Institute's new Director of the Women's Cancer Program.

Key Points: 
  • LOS ANGELES, Sept. 21, 2022 /PRNewswire/ -- The Lawrence J. Ellison Institute for Transformative Medicine announced todaythe appointmentof Dr. Reva Basho as the Institute's new Director of the Women's Cancer Program.
  • "We are thrilled to have Dr. Basho join our growing Institute team as both a highly skilled clinician and researcher," said Dr. David Agus, Founding Director and CEO of the Ellison Institute.
  • "I'm incredibly excited to join the Ellison Institute to help build a leading Women's Cancer Program," said Dr.
  • Dr. Basho joins the Institute from Cedars-Sinai Medical Center, where she served as the Co-Director of the Women's Cancer Research Program.

Tessa Therapeutics Recognized in “Most Promising Off-the-Shelf Therapies” Category at Asia-Pacific Cell & Gene Therapy Excellence Awards 2022

Retrieved on: 
Wednesday, September 14, 2022

SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .

Key Points: 
  • SINGAPORE, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced that TT11X, the companys allogeneic off-the-shelf CD30.CAR EBVST cell therapy, has been recognized in the Most Promising Off-the-Shelf Therapies category at the Asia-Pacific Cell & Gene Therapy Excellence Awards (ACGTEA) 2022 .
  • The ACGTEA 2022 Awards were held in conjunction with the 6th Cell & Gene Therapy World Asia 2022.
  • Tessa Therapeutics is a clinical-stage biotechnology company developing next-generation cell therapies for the treatment of hematological cancers and solid tumors.
  • Tessa has its global headquarters in Singapore, where the company has built a state of the art, commercial cell therapy manufacturing facility.

CCRM Fertility Expands Houston Clinic with Addition of Dr. Beth Zhou

Retrieved on: 
Tuesday, September 13, 2022

HOUSTON, Sept. 13, 2022 /PRNewswire/ -- CCRM Fertility, a global pioneer in fertility treatment, research and science, today announced Dr. Beth Zhou, a reproductive endocrinology and infertility specialist who is board-certified in obstetrics and gynecology, has joined CCRM Houston following her fellowship at University of California, San Diego (UCSD) in La Jolla, Calif. Dr. Zhou is currently accepting new patients.

Key Points: 
  • "CCRM Fertility has always been committed to building, growing and maintaining a team of physicians that share the same passion and attentiveness to personalized fertility care," said Jon Pardew, president and CEO of CCRM Fertility.
  • Dr. Zhou is a native Houstonian and attended the University of Houston where she received her bachelor's degree in biology magna cum laude.
  • Dr. Zhou practices out of the following locations: 929 Gessner Rd., Suite 2300, Houston, TX 77024 and 7400 Fannin, Suite 910, Houston, TX 77054.
  • CCRM Fertility is a global pioneer in fertility treatment, research and science.

Indonesia's Bio Farma ready to produce 'IndoVac' Covid-19 vaccines

Retrieved on: 
Sunday, September 11, 2022

After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.

Key Points: 
  • After securing all the necessary permits, Bio Farma will be ready to move on to the next stage, mass production of the vaccine.
  • All Covid-19 vaccines made by Bio Farma, including the primary series vaccines, booster vaccines and vaccines for children, will be labelled IndoVac.
  • In manufacturing the nOPV2 vaccine, Bio Farma collaborated with world-class institutions like Bill and Melinda Gates Foundation (BMGF), PATH and the WHO.
  • Bio Farma has since become the main supplier of polio vaccines in the world, and currently contributes 67 percent to the global supply of polio vaccines.